1. Home
  2. JELD vs MDWD Comparison

JELD vs MDWD Comparison

Compare JELD & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.80

Market Cap

152.5M

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$14.12

Market Cap

181.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
MDWD
Founded
1960
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Forest Products
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
181.1M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
JELD
MDWD
Price
$1.80
$14.12
Analyst Decision
Hold
Strong Buy
Analyst Count
6
1
Target Price
$3.43
$36.00
AVG Volume (30 Days)
1.4M
105.9K
Earning Date
05-04-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,211,181,000.00
N/A
Revenue This Year
N/A
$48.92
Revenue Next Year
$2.06
$35.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.93
$13.54
52 Week High
$6.98
$21.26

Technical Indicators

Market Signals
Indicator
JELD
MDWD
Relative Strength Index (RSI) 51.38 41.31
Support Level $1.64 $13.54
Resistance Level $2.15 $18.49
Average True Range (ATR) 0.19 0.55
MACD -0.03 0.07
Stochastic Oscillator 36.36 48.28

Price Performance

Historical Comparison
JELD
MDWD

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: